glp 1 prostate cancer May Patients Receiving GLP-1 Agonists Be at Lower Risk of Aggressiveness and Progression? From Diabetes to Oncology: Glucagon-like

pharmacovigilance experts are monitoring for adverse signals beyond clinical trials

doi: 10.1038/srep42394 76 ZhangYLiuLJinLYiXDangEYangYet al

Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) are also sometimes included with GLP1s, although they work a little differently

Preliminary findings from Virtas book of business indicate its prescribing solution drove transformative health outcomes and immediate business impact, including: Substantial reduction in GLP-1 utilization and corresponding costs Responsible Prescribing prevents ongoing GLP-1 use by over 50% among current GLP-1 users, lowering costs for payers

Important caveat: for OA and PsA, much of the benefit could still be secondary to weight loss itself